9
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Rapid establishment of a COVID-19 critical care unit in a convention centre: the Nightingale Hospital London experience

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dear Editor, In response to an unmet need of critical care beds in London during the first wave of the coronavirus disease 2019 (COVID-19) pandemic in late March 2020, a critical care unit was constructed over nine days in a conference center in East London. This facility, the Nightingale Hospital London (NHL, Fig. 1), had no existing infrastructure for healthcare provision. Fig. 1 Nightingale Hospital London This retrospective cohort study describes the characteristics and clinical outcomes of patients admitted to NHL compared to a national cohort of critically ill patients with confirmed COVID-19 admitted to critical care units participating in the Case Mix Programme (all NHS adult, general intensive care and combined intensive care/high dependency units in England, Wales and Northern Ireland, plus some additional specialist and non-NHS critical care units) and reported to the Intensive Care National Audit and Research Centre (ICNARC) during the first wave of the epidemic, up to 31 August 2020 (n = 10,941). All patients admitted to NHL had a confirmed or suspected COVID-19 and were invasively ventilated at the time of referral/admission. Inclusion criteria for referral and admission are outlined in Figure S1. Fifty-four patients were cared for between 7 April and 7 May with a peak of 35 patients (Figure S2). Median age was 61 years with a male bias (45/54, 83%, Table S1). The patient characteristics and severity of illness on admission to NHL were broadly similar to those reported in the national cohort with equivalent median APACHE II scores (15 vs. 15) and PaO2/FiO2 ratios (14.7 kPa vs. 15.8 kPa, Table S1). Median critical care length of stay prior to NHL admission was 4 days (range 2–16 days). Requirement for organ support and duration of organ support were similar between the NHL and national cohorts. Seven (13%) patients were extubated at NHL. Twenty (37%) patients died whilst an in-patient at NHL and a further 6/27 (11%) died following repatriation to their local critical care unit once critical care capacity in London was restored (Figure S3). Overall critical care mortality (including death in critical care following transfer from NHL) was 48.1% compared with 47.7% in the national dataset for patients requiring advanced respiratory support (Table S1). Duration of critical care amongst survivors was a median of 34.5 days (IQR 16–47 days) compared to 12 days (IQR 5–28 days, Table S1) nationally which may have reflected the absence of a tracheostomy service at NHL for safety reasons. Mortality at NHL compares favorably with international case series of over 50% for those who receive mechanical ventilation [1, 2] albeit that 50% of patients were transferred out for both clinical and non-clinical reasons (Figure S3). Further, mortality nationally in mid-April, when NHL was operational, was 67% [3, 4] and declined over time as experience of both patient and systems management evolved [5]. While criteria for transfer to NHL meant that admissions may have been biased towards more clinically stable patients, these outcomes were achieved on a site with significant logistical challenges, including no pre-existing oxygen supply. NHL opened with critical care nurse:patient ratios (1:6) and consultant:patient ratios (1:30) with no pre-established governance or operating procedures specific to the environment or staffing model. NHL was also operational at a time when there was significant uncertainty regarding optimal patient management and no proven disease-modifying pharmaceutical interventions. Whether the NHL blueprint was the optimal model of care or represented appropriate resource allocation remains moot but it was deemed necessary at a time of crisis. The operating model as originally conceived, was based on previous (influenza) pandemics. Subsequent clinical experience highlights that the clinical syndrome of COVID-19 and the spectrum and duration of multi-organ support requires comprehensive critical care capability. Future planning should account for this. Nonetheless, the need for emergency critical care capacity remains a realistic prospect for this pandemic and future viral pandemics and whilst there are challenges in accurate comparisons with other critical care units, the data herein suggest that emergency critical care in an alternative setting can be delivered efficiently and effectively. Supplementary Information Below is the link to the electronic supplementary material. Supplementary file1 (DOCX 149 KB)

          Related collections

          Most cited references3

          • Record: found
          • Abstract: found
          • Article: not found

          Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study

          Summary Background Nationwide, unbiased, and unselected data of hospitalised patients with COVID-19 are scarce. Our aim was to provide a detailed account of case characteristics, resource use, and outcomes of hospitalised patients with COVID-19 in Germany, where the health-care system has not been overwhelmed by the pandemic. Methods In this observational study, adult patients with a confirmed COVID-19 diagnosis, who were admitted to hospital in Germany between Feb 26 and April 19, 2020, and for whom a complete hospital course was available (ie, the patient was discharged or died in hospital) were included in the study cohort. Claims data from the German Local Health Care Funds were analysed. The data set included detailed information on patient characteristics, duration of hospital stay, type and duration of ventilation, and survival status. Patients with adjacent completed hospital stays were grouped into one case. Patients were grouped according to whether or not they had received any form of mechanical ventilation. To account for comorbidities, we used the Charlson comorbidity index. Findings Of 10 021 hospitalised patients being treated in 920 different hospitals, 1727 (17%) received mechanical ventilation (of whom 422 [24%] were aged 18–59 years, 382 [22%] were aged 60–69 years, 535 [31%] were aged 70–79 years, and 388 [23%] were aged ≥80 years). The median age was 72 years (IQR 57–82). Men and women were equally represented in the non-ventilated group, whereas twice as many men than women were in the ventilated group. The likelihood of being ventilated was 12% for women (580 of 4822) and 22% for men (1147 of 5199). The most common comorbidities were hypertension (5575 [56%] of 10 021), diabetes (2791 [28%]), cardiac arrhythmia (2699 [27%]), renal failure (2287 [23%]), heart failure (1963 [20%]), and chronic pulmonary disease (1358 [14%]). Dialysis was required in 599 (6%) of all patients and in 469 (27%) of 1727 ventilated patients. The Charlson comorbidity index was 0 for 3237 (39%) of 8294 patients without ventilation, but only 374 (22%) of 1727 ventilated patients. The mean duration of ventilation was 13·5 days (SD 12·1). In-hospital mortality was 22% overall (2229 of 10 021), with wide variation between patients without ventilation (1323 [16%] of 8294) and with ventilation (906 [53%] of 1727; 65 [45%] of 145 for non-invasive ventilation only, 70 [50%] of 141 for non-invasive ventilation failure, and 696 [53%] of 1318 for invasive mechanical ventilation). In-hospital mortality in ventilated patients requiring dialysis was 73% (342 of 469). In-hospital mortality for patients with ventilation by age ranged from 28% (117 of 422) in patients aged 18–59 years to 72% (280 of 388) in patients aged 80 years or older. Interpretation In the German health-care system, in which hospital capacities have not been overwhelmed by the COVID-19 pandemic, mortality has been high for patients receiving mechanical ventilation, particularly for patients aged 80 years or older and those requiring dialysis, and has been considerably lower for patients younger than 60 years. Funding None.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Outcomes from intensive care in patients with COVID‐19: a systematic review and meta‐analysis of observational studies

            The emergence of coronavirus disease 2019 (COVID-19) has led to high demand for intensive care services worldwide. However, the mortality of patients admitted to the intensive care unit (ICU) with COVID-19 is unclear. Here, we perform a systematic review and meta-analysis, in line with PRISMA guidelines, to assess the reported ICU mortality for patients with confirmed COVID-19. We searched MEDLINE, EMBASE, PubMed and Cochrane databases up to 31 May 2020 for studies reporting ICU mortality for adult patients admitted with COVID-19. The primary outcome measure was death in intensive care as a proportion of completed ICU admissions, either through discharge from the ICU or death. The definition thus did not include patients still alive on ICU. Twenty-four observational studies including 10,150 patients were identified from centres across Asia, Europe and North America. In-ICU mortality in reported studies ranged from 0 to 84.6%. Seven studies reported outcome data for all patients. In the remaining studies, the proportion of patients discharged from ICU at the point of reporting varied from 24.5 to 97.2%. In patients with completed ICU admissions with COVID-19 infection, combined ICU mortality (95%CI) was 41.6% (34.0-49.7%), I2  = 93.2%). Sub-group analysis by continent showed that mortality is broadly consistent across the globe. As the pandemic has progressed, the reported mortality rates have fallen from above 50% to close to 40%. The in-ICU mortality from COVID-19 is higher than usually seen in ICU admissions with other viral pneumonias. Importantly, the mortality from completed episodes of ICU differs considerably from the crude mortality rates in some early reports.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey

              Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appeared just over 7 months ago in Wuhan, China. Early reports from China indicated that although some cases are asymptomatic, 20% of COVID-19 cases follow a severe course, necessitating hospitalization, with a quarter of hospitalized patients requiring intensive care unit (ICU) facilities [1]. Later reports from China and other countries substantiated these data, although ICU admission rates, proportion of patients receiving invasive mechanical ventilation (IMV), and mortality rates differ considerably between studies [2]. The life-threatening form of respiratory failure, acute respiratory distress syndrome (ARDS) is a frequent complication in COVID-19 [3]. The severity of ARDS is classified into categories of mild, moderate, and severe, depending on the degree of hypoxemia [4]. Patients with moderate-to-severe ARDS require invasive mechanical ventilation (IMV) and have a poor prognosis [4]. The incidence of ARDS and specifically, moderate-to-severe ARDS, among COVID-19 patients is currently unknown [5]. We describe here the results of a survey of clinical studies reporting COVID-19-associated ARDS in hospitalized patients since the beginning of the COVID-19 pandemic in January until the end of July 2020. Our aim was to obtain a clearer picture of the incidence of COVID-19-associated ARDS in hospitalized patients on a global level, to better define the burden to healthcare systems and to inform critical care clinicians. This information should enable the prediction of requirements for hospital resources and thereby facilitate planning an appropriate and timely response in the future. We carried out regular searches of PubMed using combinations of the search terms “ARDS,” “COVID-19,” “clinical characteristics,” “clinical features,” “clinical findings,” “ICU,” “incidence,” “outcome,” and “prevalence” (last search July 31, 2020). Over 1000 publications were retrieved from which only studies reporting consecutively hospitalized patients, and giving numbers for ARDS patients and outcomes, were selected. Meta-analyses were excluded. Seventeen studies reporting results from 2486 hospitalized COVID-19 patients in five countries fitted the inclusion criteria (Tables 1 and 2). Limitations are that seven studies did not define ARDS and only one study classified patients as mild, moderate, and/or severe; the patient sample is comparatively small: twelve of the studies had less than 200 patients. Furthermore, there was heterogeneity in types of data gathered by each research group, hence for many of the studies, patient numbers did not permit calculation of all parameters (Tables 1 and 2). Table 1 Incidence of ARDS, ICU admission, IMV treatment, and outcome in hospitalized COVID-19 patients Study author, online publication date, doi Location Number of patients, N Patients with ARDS Patients transferred to ICU Patients who received IMV Mortality hospitalized patients Huang C, 24/1; doi: 10.1016/S0140-6736(20)30183-5 Wuhan, China 41 12/41 (29) 13/41 (32) 4/41 (10) 6/41 (15) Wang D, 7/2; doi: 10.1001/jama.2020.1585 Wuhan, China 138 27/138 (19) 36/138 (26) 17/138 (12) 6/138 (4) Xu X,19/2; doi: 10.1136/bmj.m606 Zhejiang, China 62 1/62 (2) 1/62 (2) 1/62 (2) 0/62 (0) Zhou F, 11/3; doi: 10.1016/S0140-6736(20)30566-3 Wuhan, China 191 59/191 (31) 50/191 (26) 32/191 (17) 54/191 (28) Wu C, 13/3; doi: 10.1001/jamainternmed.2020.0994 Wuhan, China 201 84/201 (42) 53/201 (26) 6/201 (3) 44/201 (22) Dreher M, 17/4; doi: 10.3238/arztebl.2020.0271 Aachen, Germany 50 24/50 (48) 24/50 (48) 24/50 (48) 7/50 (14) Yao Q, 24/4; doi: 10.20452/pamw.15312 Huanggang, China 108 45/108 (42) 17/108 (16) 10/108 (9) 12/108 (11) Aggarwal S, 26/4; doi: 10.1515/dx-2020-0046 Des Moines, Iowa, USA 16 5/16 (31) 8/16 (50) 5/16 (31) 3/16 (19) Inciardi R, 8/5; doi: 10.1093/eurheartj/ehaa388 Brescia, Italy 99 19/99 (19) 12/99 (12) 2/99 (2) 26/99 (26) Hong K, 11/5; doi: 10.3349/ymj.2020.61.5.431 Daegu, South Korea 98 18/98 (18) 13/98 (13) 11/98 (11) 5/98 (5) Yang L, 26/5; doi: 10.1016/j.jcv.2020.104475 Yichang, China 200 32/200 (16) 29/200 (15) 16/200 (8) 15/200 (7) Suleyman G, 1/6; doi: 10.1001/jamanetworkopen.2020.12270 Detroit, Michigan, USA 355 111/355 (31) 141/355 (40) 114/355 (32) 72/355 (20) Zheng Y, 10/4; doi: 10.1016/j.jcv.2020.104366 Chengdu, China 99 15/99 (15) 32/99 (32) NA 3/99 (3) Chen N, 30/1; doi: 10.1016/S0140-6736(20)30211-7 Wuhan, China 99 17/99 (17) NA NA 11/99 (11) Chen T, 26/3; doi: 10.1136/bmj.m1091 Wuhan, China 274a 196(NA)a NA NA 113(NA)a Yu T, 27/4; doi: 10.1016/j.clinthera.2020.04.009 Dongguan, China 95 24/95 (25) NA NA 1/95 (1) Ciceri F, 12/6; doi: 10.1016/j.clim.2020.108509 Milan, Italy 360 245/360 (68) NA NA 82/360 (23) Total (weighted average) 2486 738/2212 (33)b 429/1658 (26) 242/1559 (16) 347/2212 (16)b Data are presented as n/N(%) Abbreviations: ARDS acute respiratory distress syndrome, COVID-19 coronavirus disease 2019, ICU intensive care unit, IMV invasive mechanical ventilation, NA not available: insufficient data for calculation aFrom a hospitalized cohort of 799 COVID-19 patients, data available for 274 patients: 113 deaths and 161 recovered bPatient numbers for Chen T study not included Table 2 Incidence of ARDS, IMV treatment, and outcomes in COVID-19 patients admitted to an ICU Study author, online publication datea Location ICU patients with ARDS ICU patients who received IMV Mortality ICU patients Mortality ARDS patients Mortality IMV patients Prevalence of ARDS in non-survivors Dreher M, 17/4 Aachen, Germany 24/24 (100) 24/24 (100) 3/24 (13) 3/24 (13) 3/24 (13) 3/7 (43) Yao Q, 24/4 Huanggang, China 17/17 (100) 10/17 (59) 12/17 (71) 12/45 (27) 10/10 (100) 12/12 (100) Hong K, 11/5 Daegu, South Korea 13/13 (100) 11/13 (85) 4/13 (31) 4/18 (22) NA 4/5 (80) Xu X,19/2 Zhejiang, China 1/1 (100) 1/1 (100) 0/1 (0) 0/1 (0) 0/1 (0) NA Wu C, 13/3 Wuhan, China NA 6/53 (11) NA 44/84 (52) 6/6 (100) 44/44 (100) Zhou F, 11/3 Wuhan, China NA NA 39/50 (78) 50/59 (85) 31/32 (97) 50/54 (93) Zheng Y, 10/4 Chengdu, China 15/32 (47) NA 3/32 (9) 3/15 (20) NA 3/3 (100) Suleyman G, 1/6 Detroit, Michigan, USA 104/141 (74) 114/141 (81) 57/141 (40) NA 52/114 (46) NA Huang C, 24/1 Wuhan, China 11/13 (85) 4/13 (31) 5/13 (38) NA NA NA Wang D, 7/2 Wuhan, China 22/36 (61) 21/36 (58) 6/36 (17) NA NA NA Yang L, 26/5 Yichang, China 21/29 (72) 16/29 (55) 14/29 (48) NA NA NA Chen T, 26/3 Wuhan, China NA NA NA 113/196 (58) 17/17 (100) 113/113 (100) Aggarwal S, 26/4 Des Moines, Iowa, USA NA 5/8 (63) 3/8 (38) NA NA NA Inciardi R, 8/5 Brescia, Italy NA NA NA 17/19 (89) NA 17/26 (65) Chen N, 30/1 Wuhan, China NA NA NA 11/17 (65) NA 11/11 (100) Ciceri F, 12/6 Milan, Italy NA NA NA 65/245 (27) NA 65/82 (79) Yu T, 27/4 Dongguan, China NA NA NA NA NA NA Total (weighted average) 228/306 (75) 212/335 (63) 146/363 (40) 322/722 (45) 119/203 (59) 322/357 (90) Data are presented as n/N(%) Abbreviations: ARDS acute respiratory distress syndrome, COVID-19 coronavirus disease 2019, ICU intensive care unit, IMV invasive mechanical ventilation, NA not available: insufficient data for calculation aFor study reference see Table 1 There is variability between individual studies with respect to frequency of ARDS, rates of ICU admission, and mortality among patients. Calculation of weighted averages for these parameters incorporating data from individual studies for which data is available indicate that among hospitalized COVID-19 patients, approximately 1/3 (33%) develop ARDS, 1/4 (26%) require transfer to an ICU, 1/6 (16%) receive IMV, and 1/6 (16%) die (Table 1). For COVID-19 patients transferred to an ICU, nearly 2/3 (63%) receive IMV and 3/4 (75%) have ARDS (Table 2). The mortality rate of ICU COVID-19 patients is 40% and of those who receive IMV 59%; the mortality rate in COVID-19-associated ARDS is 45%, and the incidence of ARDS among non-survivors of COVID-19 is 90% (Table 2). The high incidence of ARDS among COVID-19 patients revealed in our survey is consistent with the results of postmortem examinations of patients with COVID-19, in which the predominant finding is diffuse alveolar damage, the most frequent histopathologic correlate of ARDS. For as long as there is neither a safe and efficacious vaccine nor therapy for severely affected COVID-19 patients, standard supportive care with lung-protective mechanical ventilation will be the cornerstone of treatment for these patients [5, 6]. The implications of these survey results are important and demonstrate the considerable challenges posed by the “COVID-19 crisis” to ICU practitioners, hospital administrators, and health policy makers. Susan Tzotzos, MSc, PhD Bernhard Fischer, PhD Hendrik Fischer, PhD Markus Zeitlinger, MD, PhD
                Bookmark

                Author and article information

                Contributors
                alastair.proudfoot1@nhs.net
                Journal
                Intensive Care Med
                Intensive Care Med
                Intensive Care Medicine
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                0342-4642
                1432-1238
                28 January 2021
                : 1-3
                Affiliations
                [1 ]GRID grid.139534.9, ISNI 0000 0001 0372 5777, Barts Health NHS Trust, ; London, UK
                [2 ]GRID grid.4868.2, ISNI 0000 0001 2171 1133, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, , Queen Mary University of London, ; London, UK
                [3 ]GRID grid.450885.4, ISNI 0000 0004 0381 1861, Intensive Care National Audit and Research Centre, ; London, UK
                [4 ]GRID grid.437485.9, ISNI 0000 0001 0439 3380, Royal Free London NHS Foundation Trust, ; London, UK
                Author information
                http://orcid.org/0000-0001-9935-0438
                Article
                6334
                10.1007/s00134-020-06334-6
                7841382
                33507320
                a4ab5b82-c8da-4507-baac-01241391cbd5
                © Springer-Verlag GmbH Germany, part of Springer Nature 2021

                This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

                History
                : 4 December 2020
                Categories
                Letter

                Emergency medicine & Trauma
                Emergency medicine & Trauma

                Comments

                Comment on this article

                scite_

                Similar content58

                Cited by10

                Most referenced authors52